Kamada Ltd. announced strong financial results for the first quarter ended March 31, 2025. Total revenues for the quarter reached $44.0 million, representing an increase of approximately 17% year-over-year. Adjusted EBITDA for the first quarter was $11.6 million, marking a significant increase of approximately 54% year-over-year.
The company reported a net income of $3.96 million for the quarter, compared to $2.37 million in the prior year, with diluted earnings per share of $0.07. Kamada reiterated its fiscal year 2025 annual guidance, expecting total revenues in the range of $178 million to $182 million and adjusted EBITDA between $38 million and $42 million.
Kamada continues to advance its strategic growth pillars, including the recently opened San Antonio plasma collection center, which is anticipated to contribute $8 million to $10 million in annual revenues at full capacity. Enrollment is progressing in the pivotal Phase III InnovAATe clinical trial, with an interim futility analysis on track for the end of 2025, and the post-marketing research program for CYTOGAM® has been initiated.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.